Artificial intelligence (AI) technologies might be able to accelerate the search for drugs effective against COVID-19, and its potential is being put to work in an initiative by the leading AI firm, Exscientia Ltd., eminent structural biology researchers at Oxford University and the UK’s synchrotron research facility, Diamond Light Source, with the help of a US compound library supplied by the Scripps Research division, Calibr.
Exscientia will use its AI-driven biosensor platforms and the synchrotron facilities at the Diamond Light Source in Harwell, UK, to screen a library of 15,000 pharmaceutical compounds collected by La Jolla, CA-based Calibr